GH Research PLC · NASDAQ:GHRS
GH Research — Corporate Update (November 2026)
19 slides from GH Research's corporate update, Nov 13, 2026
Slide 1: Ultra-Rapid, Durable Remission
Ultra-Rapid, Durable Remission November 2026
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements ‘This presentation has been prepared by GH Research PLC ("GH Research”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent,
Slide 3: GH Research — November 2026 update
GH Research — November 2026 update 1 Novel GH001 ADS device: final results of the HV-106 trial support going from 3 → 1 doses per treatment visit 2 TRD pivotal program — positive initial feedback from FDA, EoP2 expected in Q1 2027, initiation shortly after 3 PPD pivotal program — initiation targeted
Slide 4: Pipeline
Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Status Treatment-resistant depression (TRD) Positive initial feedback from FDA, EoP2 meeting expected in Q1 2027 Pivotal program initiation shortly after Postpartum depression (PPD) Pivotal program initiation targete
Slide 5: Old GH001 VM device: titration to peak experience
Old GH001 VM device: titration to peak experience One fixed dose VM devices, single dose of 6, 12 or 18 mg; 74 participants, four trials 45% 44% Any of the three doses 33 of 74 Highest dose, 18 mg 7 of 16 Titration in Phase 2b — cumulative peak experience reached after each dose VM device; next dose
Slide 6: New GH001 ADS: delivers consistent dose through reduced variability
New GH001 ADS: delivers consistent dose through reduced variability How much of each dose is delivered: each dot is one dose Delivered-dose bench test under controlled conditions 60% 70% 80% 90% 100% Old GH001 VM 55–79% New GH001 ADS 82–89% n=30 n=30 Abbreviations: ADS = Aerosol Delivery System; VM
Slide 7: 3 → 1: one fixed dose with GH001 ADS achieved 88% peak experience rate
3 → 1: one fixed dose with GH001 ADS achieved 88% peak experience rate Device properties GH001 VM GH001 ADS Share of the loaded dose delivered 55–79% 82–89% Delivered dose in particles under 3 µm 89% 99% Inhaling the full dose Balloon Chamber with air bypass Dose preparation steps 70% reduction Aero
Slide 8: GH001 is built for the interventional psychiatry workflow
GH001 is built for the interventional psychiatry workflow GH001¹ SPRAVATO®² Setting Outpatient clinics by qHCPs and clinical staff Outpatient clinics by qHCPs and clinical staff Psychotherapy No mandated psychotherapy No mandated psychotherapy Treatments per visit 1 per visitᵃ 1 per visit WHERE GH00
Slide 9: SPRAVATO proves the clinic model
SPRAVATO® proves the clinic model SPRAVATO® worldwide net sales, $bn (2026 estimated)¹ Remission (MADRS ≤10): GH001 and SPRAVATO®² Abbreviations: MADRS = Montgomery-Åsberg Depression Rating Scale; VM = Volcano Medic vaporizers. Notes: To-date, no head-to-head comparisons of any other products to any
Slide 10: GH001 ADS: the shortest psychoactive experience
GH001 ADS: the shortest psychoactive experience Abbreviations: ADS = Aerosol Delivery System; h = Hours; min = Minutes; TRD = Treatment-resistant depression; VM = Volcano Medic vaporizers. Notes: To-date, no head-to-head comparisons of any other products to any of our product candidates have been co
Slide 11: A fixed ~1-hour visit — and 83% fewer visits than Spravato
A fixed ~1-hour visit — and 83% fewer visits than Spravato®ᶠ Time in clinic per treatment visit (hours) ~1 h, fixed ≥2 h 1.5–2 h ~2 h 6–8 h GH001 new ADS pivotal, one fixed doseᵃ SPRAVATO® monitoring, approvedᵇ BPL-003 discharge-ready, Phase 2bᶜ VLS-01 design target, Phase 2bᵈ COMP360 Phase 3ᵉ Treat
Slide 12: Pivotal program: positive initial feedback from FDA, EoP2 expected in Q1 2027
Pivotal program: positive initial feedback from FDA, EoP2 expected in Q1 2027 PROPOSED GH001 PIVOTAL DESIGN IN TRD - TO BE FINALIZED AT EoP2 Randomized, double-blind — parallel dose arms versus placebo Re-treatment before Week 4 Re-treatment from Week 4 to Week 12 Open-label extension Day 1 One fixe
Slide 13: Postpartum depression (PPD)
Postpartum depression (PPD) 1 Common and serious: ~500k US women develop PPD each year Mental health conditions are the #1 cause of US pregnancy-related death 2 GH001 Phase 2a: 10 of 10 in remission after a single administration day Remission (MADRS ≤10) at 2 hours, on Day 2 and on Day 8 3 Growing d
Slide 14: PPD is common and serious
PPD is common and serious ~500k US women develop PPD each year (GH estimate)¹˒² #1 cause of US pregnancy-related deaths: mental health conditions, incl. suicide³ 1 in 5 mothers who screen positive have thoughts of self-harm⁴ 7× odds of depression at age 18 in children of mothers whose severe PPD per
Slide 15: GH001 in PPD: remission after a single administration day
GH001 in PPD: 10 of 10 in remission after a single administration day¹ MADRS total score: each patient (gray) and mean (teal)ᵃ 0 10 20 30 40 50 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Baseline 36.7 2 h: 5.3 0.7 1.3 Day 8: −35.4 points, the primary endpoint¹ Remission threshold (MADRS ≤10) Ad
Slide 16: ZURZUVAE shows growing demand with daily administrations
ZURZUVAE® shows growing demand with 14 daily administrations ZURZUVAE® net revenue by quarter, $m¹ — 12 quarters since launch (December 2023) 1.6 12.4 14.9 22.0 22.9 27.7 46.4 55.3 65.7 55.4 70.8 84.4 Q4’23 Q1’24 Q2’24 Q3’24 Q4’24 Q1’25 Q2’25 Q3’25 Q4’25 Q1’26 Q2’26 Q3’26 +53% revenue growth y/y, Q3
Slide 17: Efficacy in PPD
Efficacy in PPD MADRS reduction from baseline (points) −35.4 −23.0 −19.7 GH001 Day 8 open-label, n=10ᵃ Luvesilocin Day 7, n=35 low dose −17.2ᵇ ZURZUVAE® Day 15, n=98 placebo −14.6ᶜ Patients in remission (MADRS ≤10) 100% 71% 41% GH001 10 of 10 2 h, Day 2, Day 8ᵃ Luvesilocin Day 7, n=35 low dose 41%ᵇ
Slide 18: Multi-layer IP and regulatory protection into the 2040s
Multi-layer IP and regulatory protection into the 2040s OG REGULATORY EXCLUSIVITY 5S years +2.5 years paragraph IV stay 10 years +1 year for a new indication PATENTS Earliest patent filings relating to mebufotenin (including pending applications): Novel aerosol compositions of Novel uses in various
Slide 19: GH Research — November 2026 update
GH Research — November 2026 update 1 Novel GH001 ADS device: final results of the HV-106 trial support going from 3 → 1 doses per treatment visit 2 TRD pivotal program — positive initial feedback from FDA, EoP2 expected in Q1 2027, initiation shortly after 3 PPD pivotal program — initiation targeted